Considering taking medication to treat amyloid light chain amyloidosis? Below is a list of common medications used to treat or reduce the symptoms of amyloid light chain amyloidosis. Follow the ...
Amyloid and SARS-CoV-2; Alzheimer's Drug Failure; Who Benefits From Brain Training?
The investigational anti-amyloid drug crenezumab did not show significant clinical benefit in a trial of cognitively healthy people with autosomal dominant Alzheimer's disease in Colombia, Genentech ...
New Alzheimer's drug delivers disappointing results
In a controversial move last year, the U.S. Food and Drug Administration granted its first approval of an anti-amyloid drug, Aduhelm, despite acknowledging that it was unclear if the drug could ...
Moving Beyond Anti-amyloid Therapy for the Prevention and Treatment of Alzheimer's Disease
Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to treat AD with anti-amyloid therapies. Discussion These therapies are based ...
Why the world's still waiting for a dementia cure, and what we can do in the meantime
The trouble is, for at least 20 years, every anti-amyloid drug that's been produced has failed to definitively prove they can halt or slow cognitive decline. There may be a few reasons for this.
Amyloidosis and the respiratory tract
Such “anti-amyloid” drugs, some of which are presently under development, should be available for treatment of patients with amyloidosis in the near future. This work was supported in part by Medical ...
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
this study design allows the researchers to assess whether amyloid removal clears the way for the anti-tau drug to function most effectively. Pre-symptomatic participants will be randomly assigned ...
Alzheimer's drug with high hopes fails to slow or halt disease with early treatment
The Colombia study that began enrolling patients in 2013 sought to test the idea that early treatment could delay of prevent Alzheimer's disease.
Trial of New Alzheimer’s Drug Reports Disappointing Results
The drug, crenezumab, failed to prevent early symptoms or slow cognitive decline, the latest setback in the long quest to find effective therapies for the disease.
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
